DDInter1377 DDInter1435
Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Paclitaxel {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cabazitaxel
Paclitaxel {u} (Compound) resembles {v} (Compound) Docetaxel
Paclitaxel {u} (Compound) treats {v} (Disease) breast cancer
Paclitaxel {u} (Compound) binds {v} (Gene) CYP3A5
Paclitaxel {u} (Compound) upregulates {v} (Gene) CDCA8
Paclitaxel {u} (Compound) is included by {v} (Pharmacologic Class) Microtubule Inhibition
Paclitaxel {u} (Compound) downregulates {v} (Gene) SCAND1
Paclitaxel {u} (Compound) causes {v} (Side Effect) Swelling face
Paclitaxel {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sparfloxacin
Paclitaxel {u} may cause a minor interaction that can limit clinical effects when taken with {v} Delafloxacin
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
Paclitaxel (Compound) resembles Docetaxel (Compound)
Paclitaxel (Compound) treats breast cancer (Disease)
Paclitaxel (Compound) binds CYP3A5 (Gene)
Paclitaxel (Compound) upregulates CDCA8 (Gene)
Paclitaxel (Compound) is included by Microtubule Inhibition (Pharmacologic Class)
Paclitaxel (Compound) downregulates SCAND1 (Gene)
Paclitaxel (Compound) causes Swelling face (Side Effect)
Paclitaxel may cause a minor interaction that can limit clinical effects when taken with Sparfloxacin
Paclitaxel may cause a minor interaction that can limit clinical effects when taken with Delafloxacin